Status:
UNKNOWN
Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications
Lead Sponsor:
German Diabetes Center
Collaborating Sponsors:
Heinrich-Heine University, Duesseldorf
Conditions:
Obesity
Type 2 Diabetes
Eligibility:
All Genders
40-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The investigators aim to test the hypothesis that Lactobacillus Reuteri-enriched microbiota improves insulin sensitivity and glucose tolerance in obese healthy and obese type 2 diabetes patients by im...
Detailed Description
Prediabetes and diabetes are accompanied by insufficient gut hormone release, insulin resistance, insufficient insulin secretory capacity and low grade systemic inflammation. Results of recent animal ...
Eligibility Criteria
Inclusion
- Obese subjects: age 40 - 65 years, obesity (BMI 30-45 kg/m2), non-smoking, absence of gastrointestinal disease, willingness to abstain from intake of fermented milk products over a study period of 8 weeks.
- Healthy control subjects: non-obese (BMI 19-25 kg/m2), non-diabetic subjects, matched for age and sex, non-smoking, absence of gastrointestinal disease, willingness to abstain from intake of fermented milk products over a study period of 8 weeks.
Exclusion
- pregnancy, cancer, chronic diseases, antibiotic therapy, competitive athletes.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01250106
Start Date
November 1 2010
End Date
December 1 2011
Last Update
July 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
German Diabetes Center
Düsseldorf, Duesseldorf, Germany, 40225